<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>American Century One Choice Blend+ 2060 Portfolio R Class — News on 6ix</title>
    <link>https://6ix.com/company/american-century-one-choice-blend-2060-portfolio-r-class</link>
    <description>Latest news and press releases for American Century One Choice Blend+ 2060 Portfolio R Class on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/american-century-one-choice-blend-2060-portfolio-r-class" rel="self" type="application/rss+xml" />
    <item>
      <title>Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States</title>
      <link>https://6ix.com/company/american-century-one-choice-blend-2060-portfolio-r-class/news/wave-life-sciences-announces-hearing-on-proposed-redomiciliation-to-the-united-states-12</link>
      <guid isPermaLink="true">https://6ix.com/company/american-century-one-choice-blend-2060-portfolio-r-class/news/wave-life-sciences-announces-hearing-on-proposed-redomiciliation-to-the-united-states-12</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma</title>
      <link>https://6ix.com/company/american-century-one-choice-blend-2060-portfolio-r-class/news/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hlaa2-negative-metastatic-uveal-melanoma-2</link>
      <guid isPermaLink="true">https://6ix.com/company/american-century-one-choice-blend-2060-portfolio-r-class/news/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hlaa2-negative-metastatic-uveal-melanoma-2</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today</description>
    </item>
  </channel>
</rss>